Home › Amyloidosis › Washington › Seattle
Amyloidosis clinical trials in Seattle, WA
4 studies for Amyloidosis are looking for participants at sites in and around Seattle (within about 30 miles). Open a study to see who can join and how to contact the study team.
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RecruitingObservational study
- Research Site, Seattle
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
RecruitingPhase 3
- Clinical Trial Site, Seattle
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- University of Washington Medical Center, Seattle
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
RecruitingPhase 1/2
- University of Washington /ID# 261581, Seattle
About Amyloidosis
Amyloidosis is a rare condition that can affect different organs of the body. Find out about amyloidosis treatment and symptoms.
More about Amyloidosis on MedlinePlus
Amyloidosis trials in other cities
- Boston, MA11 studies
- Rochester, MN10 studies
- New York City, NY10 studies
- Dallas, TX9 studies
- Philadelphia, PA7 studies
- St. Louis, MO6 studies
- Baltimore, MD6 studies
- Houston, TX6 studies
- Durham, NC6 studies
- Portland, OR6 studies
- Washington, DC5 studies
- San Diego, CA5 studies
Other studies in Seattle
- Non-Small Cell Lung Cancer53 studies
- Cancer (all types)50 studies
- Prostate Cancer44 studies
- Acute Myeloid Leukemia40 studies
- Breast Cancer40 studies
- Metastatic Cancer39 studies
- Colorectal Cancer34 studies
- Lung Cancer33 studies
- Ovarian Cancer31 studies
- Pancreatic Cancer22 studies
- Multiple Myeloma22 studies
- Acute Lymphoblastic Leukemia21 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.